Zocor
$ 30,00 – $ 361,00Price range: $ 30,00 through $ 361,00
Zoloft
$ 35,00 – $ 214,00Price range: $ 35,00 through $ 214,00
Zofran
$ 44,00 – $ 258,00Price range: $ 44,00 through $ 258,00
Zofran is a trusted medication specifically designed to prevent nausea and vomiting caused by chemotherapy, radiation therapy, and surgery. The active ingredient works by blocking serotonin, a natural chemical in the body that can trigger the urge to vomit. It is widely recognized for its effectiveness in helping patients maintain their comfort during intensive medical treatments. This medication is also an excellent option for managing post-operative recovery by reducing the risk of gastrointestinal distress after anesthesia. Zofran provides a reliable solution for those seeking effective relief from treatment-related nausea.
Active substance: Ondansetron
SKU:
Zofran
Categories: Cancer, Gastrointestinal Tract
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM
Each dosage option has its own packaging choices.
Description
Zofran belongs to a class of medications known as selective serotonin 5-HT3 receptor antagonists, prescribed primarily to prevent nausea and vomiting associated with specific medical procedures and therapies. In the United States, this medication is available by prescription only under federal regulations and must be administered according to a licensed healthcare provider’s guidance.
The active ingredient in Zofran is ondansetron, which targets specific peripheral and central nervous system receptors to interrupt the emetic signal cascade. Understanding its mechanism of action, proper administration guidelines, potential drug interactions, and safety profile helps ensure optimal therapeutic outcomes while mitigating adverse effects.
| Parameter | Details |
|---|---|
| Active Ingredient | Ondansetron hydrochloride |
| Therapeutic Class | 5-HT3 receptor antagonist |
| Dosage Forms | Oral tablet, orally disintegrating tablet (ODT), oral solution, injection |
| Route of Administration | Oral, Intravenous |
| Primary Purpose | Prevention of chemotherapy, radiation, and postoperative nausea and vomiting |
| Prescription Status | Prescription (Rx) only |
Clinical Profile and Pharmacological Properties
How the drug works
Zofran exerts its pharmacological effect as a selective 5-HT3 receptor antagonist. During emetogenic medical treatments such as cancer chemotherapy or surgical intervention, mucosal enterochromaffin cells in the small intestine release serotonin (5-hydroxytryptamine). This released serotonin stimulates 5-HT3 receptors located on vagal afferent nerves, which initiate the vomiting reflex transmitted to the solitary tract nucleus and chemoreceptor trigger zone in the central nervous system. Ondansetron selectively blocks these 5-HT3 receptors both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone. By blocking serotonin binding, Zofran interrupts the neural pathways that trigger acute nausea and retching responses.
What it’s used for
Zofran is indicated for several specific FDA-approved clinical scenarios. It is approved for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic regimens containing cisplatin. Additionally, it is indicated for the prevention of nausea and vomiting associated with radiotherapy, including total body irradiation, single high-dose fraction, or daily fractionated abdominal radiation. Another primary indication includes the prevention of postoperative nausea and vomiting (PONV) following surgical procedures. Prescribers may occasionally evaluate ondansetron off-label for conditions such as severe gastroenteritis-induced vomiting; however, off-label uses must be specifically evaluated and directed by a healthcare professional due to limited risk-benefit determinations in non-approved settings.
Dosing schedule
Dosing schedules for Zofran depend on the clinical indication, patient age, route of administration, and specific formulation prescribed. For adult chemotherapy-induced nausea prevention, typical oral dosages range from 8 mg to 24 mg administered prior to therapy, followed by scheduled doses as directed by the clinician. For postoperative nausea prevention, a standard oral dose of 16 mg may be administered one hour prior to anesthesia induction, or 4 mg may be administered intravenously immediately prior to or following anesthesia. Orally disintegrating tablets (ODT) should be placed on top of the tongue with dry hands, allowed to dissolve completely without chewing, and swallowed with saliva. Dose adjustments are required in patients with severe hepatic impairment, where the total daily dosage should not exceed 8 mg.
What happens in the body
Following oral administration, ondansetron is absorbed from the gastrointestinal tract and undergoes first-pass metabolism. The systemic bioavailability of Zofran oral tablets is approximately 60%. Peak plasma concentrations are reached approximately 1.5 to 2 hours after oral ingestion. The drug is extensively bound to plasma proteins (70% to 76%). Ondansetron is extensively metabolized in the liver via multiple cytochrome P450 enzyme pathways, primarily CYP3A4, CYP2D6, and CYP1A2. The terminal elimination half-life of ondansetron in healthy adult subjects is approximately 3 to 4 hours, though this half-life may extend to 6 to 8 hours in elderly patients or up to 20 hours in individuals with severe hepatic impairment. Metabolites are excreted primarily through the renal route.
Compatibility with other medicines
Zofran can interact with several classes of medications, potentially altering clinical efficacy or increasing the risk of serious adverse events. Concomitant use with apomorphine is strictly contraindicated due to reports of severe hypotension and loss of consciousness. Co-administration of ondansetron with other agents that prolong the QT interval–such as antiarrhythmics (amiodarone, sotalol), certain antipsychotics (haloperidol, quetiapine), fluoroquinolone antibiotics, and macrolides–increases the risk of severe cardiac arrhythmias including Torsades de Pointes. Inducers of CYP3A4, such as rifampin or carbamazepine, may increase ondansetron clearance and decrease blood levels. Serotonergic drugs, including SSRIs, SNRIs, and MAO inhibitors, combined with Zofran increase the risk of serotonin syndrome.
Safety Profile, Side Effects, and Guidelines
Adverse reactions
Adverse reactions to Zofran vary in frequency and severity among patients. The most common mild-to-moderate side effects observed in clinical trials include headache, fatigue, constipation, drowsiness, and transient dizziness. Gastrointestinal symptoms such as diarrhea or localized sensation of warmth/flushing during intravenous administration may also occur. Less common but potentially severe adverse effects involve cardiovascular system alterations, including electrocardiographic changes such as QT interval prolongation, PR interval prolongation, and bradycardia. Hypersensitivity reactions, including anaphylaxis, bronchospasm, and urticaria, have been reported. Patients experiencing severe constipation should monitor for symptoms of ileus, as ondansetron decreases gastrointestinal motility.
Important precautions
Special clinical precautions are necessary when prescribing or administering Zofran to high-risk populations. Ondansetron causes dose-dependent prolongation of the QT interval on electrocardiograms, which can lead to life-threatening ventricular arrhythmias such as Torsades de Pointes. Patients with congenital long QT syndrome, electrolyte abnormalities (such as hypokalemia or hypomagnesemia), congestive heart failure, or those taking concomitant QT-prolonging agents require baseline and periodic ECG monitoring. In patients with severe hepatic impairment (Child-Pugh score 10 or greater), the total daily dose must not exceed 8 mg. Use during pregnancy should be carefully weighed against alternative treatments; while prescribed in clinical settings, clinicians evaluate individual benefit-risk profiles regarding potential fetal development factors. Pediatric dosing must be strictly based on body surface area or age-specific protocols under direct medical direction.
What to avoid while taking it
Zofran oral tablets and disintegrating tablets may be taken with or without food, as food intake produces a slight increase in absorption rate without significantly altering overall systemic exposure. Alcohol consumption does not directly interact with ondansetron’s metabolic pathway; however, alcohol can exacerbate central nervous system side effects such as drowsiness, sedation, and dizziness. Patients should avoid combining Zofran with over-the-counter herbal supplements that affect serotonin levels (such as St. John’s Wort) without prior consultation with a healthcare provider.
Red flags
Patients must seek emergency medical care immediately if they experience any signs of a severe allergic or cardiovascular reaction while taking Zofran. Key red flags include:
- Sudden chest pain, palpitations, or an abnormally fast or irregular heartbeat.
- Unexplained fainting, severe lightheadedness, or sudden loss of consciousness.
- Swelling of the face, lips, tongue, or throat causing difficulty swallowing or breathing.
- Symptoms of serotonin syndrome, such as high fever, agitation, muscle stiffness, tremors, or hallucinations.
- Severe abdominal pain or inability to pass stool accompanied by severe abdominal distension.
If you skip a dose
If a scheduled dose of Zofran is missed, it should be taken as soon as remembered, provided it is not close to the time for the next scheduled dose. If the next scheduled dose is imminent, skip the missed dose and resume the regular dosing schedule. Patients should never double the dose to make up for a missed administration. Because Zofran is frequently taken on an as-needed basis for acute symptoms, strict timing applies primarily to pre-treatment schedules prescribed by a physician.
Storage and expiration
Zofran tablets, oral solution, and orally disintegrating tablets should be stored at controlled room temperature between 68°F and 77°F (20°C to 25°C), away from excessive heat, moisture, and direct light exposure. Keep the medication in its original packaging or blister pack until immediately before administration to protect orally disintegrating tablets from moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the container packaging.
Common questions
How quickly does Zofran start working after ingestion?
Oral Zofran formulations typically begin to exert an antiemetic effect within 30 to 60 minutes after administration. Peak concentration levels in the bloodstream are reached within 1.5 to 2 hours following oral ingestion.
Is Zofran indicated for the treatment of motion sickness?
Zofran is not FDA-approved for motion sickness. Motion sickness involves vestibular pathways mediated primarily by histamine and acetylcholine receptors, whereas ondansetron specifically targets serotonin 5-HT3 receptors. Motion sickness is typically managed with antihistamines or anticholinergic agents under medical advice.
Can Zofran cause heart rhythm abnormalities?
Yes, Zofran can prolong the QT interval on an electrocardiogram. While uncommon in healthy individuals, this effect increases the risk of serious cardiac arrhythmias in patients with underlying heart conditions, electrolyte imbalances, or those taking other QT-prolonging medications.
What should be done if vomiting occurs shortly after taking Zofran?
If vomiting occurs within 30 minutes of taking an oral Zofran tablet, contact the prescribing clinician or pharmacist to determine if another dose should be administered or if an alternative formulation, such as an orally disintegrating tablet or intravenous injection, is required.
Does Zofran impair mental alertness or cause drowsiness?
Drowsiness and fatigue are recognized adverse reactions associated with Zofran. Patients should observe how the medication affects them before driving, operating heavy machinery, or performing activities requiring full mental alertness.
In accordance with FDA requirements.
This content is informational and does not replace a consultation with your doctor or pharmacist.
Additional information
| Dosage |
4mg ,8mg |
|---|---|
| Package |
60 pills ,90 pills ,120 pills ,180 pills ,270 pills ,360 pills |
| Ενεργός Ουσία |
Related products
Ascorbic Acid
$ 58,00 – $ 69,00Price range: $ 58,00 through $ 69,00
Active substance: Ascorbic Acid
More Details
This product has multiple variants. The options may be chosen on the product page
Biaxin
$ 107,00 – $ 427,00Price range: $ 107,00 through $ 427,00
Active substance: Clarithromycin
More Details
This product has multiple variants. The options may be chosen on the product page
Dulcolax
$ 44,00 – $ 148,00Price range: $ 44,00 through $ 148,00
Active substance: Bisacodyl
More Details
This product has multiple variants. The options may be chosen on the product page
Florinef
$ 51,00 – $ 367,00Price range: $ 51,00 through $ 367,00
Active substance: Fludrocortisone
More Details
This product has multiple variants. The options may be chosen on the product page
Hytrin
$ 57,00 – $ 451,00Price range: $ 57,00 through $ 451,00
Active substance: Terazosin
More Details
This product has multiple variants. The options may be chosen on the product page
Lasuna
$ 58,00 – $ 244,00Price range: $ 58,00 through $ 244,00
Active substance: extracts of garlic
More Details
This product has multiple variants. The options may be chosen on the product page
Meclizine
$ 47,00 – $ 143,00Price range: $ 47,00 through $ 143,00
Active substance: Meclizine
More Details
This product has multiple variants. The options may be chosen on the product page
Nexium
$ 20,00 – $ 178,00Price range: $ 20,00 through $ 178,00
Active substance: esomeprazole
More Details
This product has multiple variants. The options may be chosen on the product page
